Simple way to explain primary haemostatic anomalies
Easy to teach
Platelet function as well as disorders of granules and their release reaction. A reader will find a few better resources.
Outline is from introduction to explanation of every single anomaly. Happy reading
Simple way to explain primary haemostatic anomalies
Easy to teach
Platelet function as well as disorders of granules and their release reaction. A reader will find a few better resources.
Outline is from introduction to explanation of every single anomaly. Happy reading
An Octogenarian Patient Of Intracapsular Neck Of Femur Fracture With Pre-oper...DrShinyKajal
Pre-operative Thrombocytopenia
collection and preparation of sdp single donor platelets
Hb, pt inr, platelet counts
apheresis
principle
donation criteria
sdp vs rdp
guidelines for platelet transfusion
etiologies of thrombocytopenia
isolated thrombocytopenia management
first line second line management
A case presentation of Exchange Transfusion in new born infant with Neonatal ...DrShinyKajal
A case of Exchange Transfusion in new born infant with Neonatal Jaundice and Rh incompatibility
transfusion management
double volume exchange transfusion
follow up at blood centre
antibody screening
direct antiglobulin test
technique
AABB standards
reconstituted whole blood
hyperbilirubinemia
kernicterus
encephalopathy
hematocrit and volume
Hemolytic disease of the fetus and newborn
Antigens which can cross placenta
RH immunoglobulin administration
RhIg
More Related Content
Similar to Platelet disorders- qualitative and quantitative
An Octogenarian Patient Of Intracapsular Neck Of Femur Fracture With Pre-oper...DrShinyKajal
Pre-operative Thrombocytopenia
collection and preparation of sdp single donor platelets
Hb, pt inr, platelet counts
apheresis
principle
donation criteria
sdp vs rdp
guidelines for platelet transfusion
etiologies of thrombocytopenia
isolated thrombocytopenia management
first line second line management
A case presentation of Exchange Transfusion in new born infant with Neonatal ...DrShinyKajal
A case of Exchange Transfusion in new born infant with Neonatal Jaundice and Rh incompatibility
transfusion management
double volume exchange transfusion
follow up at blood centre
antibody screening
direct antiglobulin test
technique
AABB standards
reconstituted whole blood
hyperbilirubinemia
kernicterus
encephalopathy
hematocrit and volume
Hemolytic disease of the fetus and newborn
Antigens which can cross placenta
RH immunoglobulin administration
RhIg
A Case presentation of Massive Transfusion in post LSCS PPH patientDrShinyKajal
workup at blood centre
components issued
transfusion summary
criteria for massive transfusion
goal of massive transfusion
Indication protocol for massive transfusion for whole blood, prbc, ffp, cryo, platelets
Targets of resuscitation in massive blood loss
Complications of Massive Transfusion
citrate toxicity
lethal triad
case presentation on diagnosis of beta thalassemia majorDrShinyKajal
case history of 9 month old infant
Paediatric Clinical Approach to this case
examination
workup at blood centre
HPLC screening
laboratory findings
screening of father mother
prominent facial features
PBF and bone marrow findings
usg abdomen
xray skull
prbc transfusion therapy in thalassemia major
classification of thalassemia
national burden in india
pathogenesis- anemia skull bone iron overload
world thalassemia day
Troubleshooting in Transfusion transmissible infection TTI laboratoryDrShinyKajal
Checklist of categories for troubleshooting in TTI
Factors affecting Troubleshooting in TTI Lab
controls used in assay testing
Principles and Practices of ELISA and Rapid for TTI Screening
Equipment Management in TTI Laboratory
calibration of equipments used
Documentation and Records in TTI Laboratory
Root Cause Analysis and Process Improvement in TTI Laboratory
External Quality Assessment Scheme and Proficiency Testing
Waste management in transfusion centre
Principle of Troubleshooting in TTI Lab
Case presentation onHeterozygous variant of Hemoglobin EDrShinyKajal
case presentation on heterozygous hemoglobin E
investigations
HPLC high performance liquid chromatography test
HbA2
fetal hemoglobin values in different variants of hempglobin
hemoglobinopathies
HbS, HbE, HbD
Case presentation on Antibody screening- how to solve 3 cell and 11 cell panel?DrShinyKajal
Blood group antibodies
different reaction grades
test material required for antibody identification
procedure
antibody screening using 2-3 cell panel
antibpdy identification using 11 cell panel
immediate spin phase
37 degree c
ahg phase
check cells
interpretation antibody workups
enzyme technique
Tissue Banking and Umbilical Cord Blood BankingDrShinyKajal
Umbilical cord blood vs bone marrow vs peripheral stem cells
indications of stem cell transplant
Regulatory requirements for cord blood banking
Requirements for processing, testing and storage areas for UCB
Air-handling system
Personnel for Cord Blood Bank
Collection of processed UCB component
procedure- in utero ex utero
transportation
processing
freezing
storage
screening tests
quality control
advantages and disadvantages
labelling
tissue collection
live and deceased donors
Transfusion support in Surgery- elective surgery, cardiac surgery, MSBOS, Tra...DrShinyKajal
AABB indications
Elective surgeries- Maximum surgical blood ordering schedule
Anemia and surgery- including Transfusion Trigger
Surgery and coagulation disorders- including factor replacement
Transfusion in cardiac surgeries- including autologous transfusion
Patient Blood management in surgery
Allogenic Transfusion
Autologous Transfusion- Intra And Postoperative Red Cell Salvage, Haemodilution
Blood Substitutes
Haematopoietic Factors
Antifibrinolytics
Fibrin Sealants
Conjugated Oestrogens.
AABB pretransfusion testing schemes
Type and screen
Maximum surgical blood ordering schedule
transfusion trigger for surgery
factor replacement in surgery
autologous transfusion
cell salvage
perioperative
massive transfusion protocol
pathogen inactivation of cellular components.pptxDrShinyKajal
Chemical inactivation
Photo-inactivation
Solvent-detergent Plasma
Photosensitizers
Methylene Blue light treatment
Psoralen Ultraviolet Light Treatment
Riboflavin Light Treatment
INTERCEPT System
Mirasol system
Platelet and plasma Pathogen Inactivation
FRALE and azridine compounds
1. Bio preservation of Red Cell Components 2. CULTURED RBCs 3. solvent plasmaDrShinyKajal
1. Bio preservation of Red Cell Components
2. CULTURED RBCs
3. Solvent plasma
Hypothermic storage
Cryopreservation
Lyophilization
Desiccated RBCs
Three major sources of cells are under consideration:
circulating stem and progenitor cells from adults or from cord blood
immortalized progenitors
pluripotent stem cells.
Immortalized Progenitors
LIQUID CULTURE METHODS- by the SED (stem cell factor (SCF), erythropoietin, and dexamethasone) and STIF cocktails (stem cell factor, thombopoietin, insulin-like growth factor-2, fibroblast growth factor-2)
ENUCLEATION- separation of extruded nuclei from cRBCs
SCALING UP- using cord blood CD34+ cells in bioreactors
and treated for 4 h with TNBP (tri-nitrobutylphosphate)solvent and with Triton X-100 detergent
Storage of Blood Components- equipments, effects of improper storage, transpo...DrShinyKajal
Introduction
Equipments required
Harmful effects of improper storage
Storage of various blood components- AABB guidelines
NACO guidelines for storage
Storage during transport
Storage in frozen state
Physical and chemical changes in stored blood
Human Stem Cells- Introduction
Types of HSC transplants
Indications
Sources of stem cells
Collection and mobilization
Types of Mobilizing agents
Processing
Cryopreservation and storage
PBSC Transplant
Quality control
Complications
TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edit...kevinkariuki227
TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edition by Laurie Kennedy-Malone, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK For Advanced Practice Nursing in the Care of Older Adults, 2nd Edition by Laurie Kennedy-Malone, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK For Timby's Introductory Medical-Surgical Nursing, 13th American Ed...kevinkariuki227
TEST BANK For Timby's Introductory Medical-Surgical Nursing, 13th American Edition by Donnelly-Moreno, Verified Chapters 1 - 72, Complete Newest Version.pdf
TEST BANK For Timby's Introductory Medical-Surgical Nursing, 13th American Edition by Donnelly-Moreno, Verified Chapters 1 - 72, Complete Newest Version.pdf
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Mastering Wealth: A Path to Financial FreedomFatimaMary4
### Understanding Wealth: A Comprehensive Guide
Wealth is a multifaceted concept that extends beyond mere financial assets. It encompasses a range of elements including money, investments, property, and other valuable resources. However, true wealth also includes non-material aspects such as health, relationships, and personal fulfillment. This guide delves into the various dimensions of wealth, exploring how it can be created, sustained, and enjoyed.
#### Defining Wealth
Traditionally, wealth is defined as the abundance of valuable resources or material possessions. It includes financial assets like cash, savings, stocks, bonds, and real estate. However, a broader understanding of wealth considers factors such as personal well-being, emotional health, social connections, and intellectual growth. This holistic view recognizes that true wealth is not solely about accumulating money but also about enhancing one's quality of life.
#### The Importance of Financial Wealth
Financial wealth remains a critical component of overall wealth. It provides security, freedom, and the ability to pursue opportunities. Key elements of financial wealth include:
1. **Savings**: Money set aside for future use. It is crucial for emergencies, large purchases, and financial goals.
2. **Investments**: Assets purchased with the expectation that they will generate income or appreciate over time. Common investments include stocks, bonds, mutual funds, real estate, and businesses.
3. **Income**: Regular earnings from work, investments, or other sources. Consistent income is essential for maintaining and growing wealth.
4. **Debt Management**: Effectively managing debt ensures that it does not erode financial wealth. This includes paying off high-interest debt and using credit wisely.
#### Creating Wealth
Creating wealth involves generating and accumulating financial and non-financial resources. The process can be broken down into several key strategies:
1. Education and Skill Development: Investing in education and skills enhances earning potential. Higher education, professional certifications, and continuous learning can lead to better job opportunities and higher salaries.
2. Entrepreneurship: Starting and running a successful business can be a significant source of wealth. Entrepreneurship requires innovation, risk-taking, and effective management.
3. Investing: Making smart investments is essential for wealth creation. This involves understanding different types of investments, assessing risks, and making informed decisions. Diversifying investments can reduce risk and increase potential returns.
4. Saving and Budgeting: Effective saving and budgeting help accumulate wealth over time. Setting financial goals, creating a budget, and sticking to it are foundational steps in wealth creation.
5. Real Estate: Investing in property can provide rental income and capital appreciation. Real estate is a tangible asset that can hedge against inflation
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
1. Presented by- Dr. Shiny
QUALITATIVE AND QUANTITATIVE
Presenter- Dr. Shiny
Moderator- Dr. Anshul Gupta
2.
3.
4.
5.
6.
7. THROMBOCYTOPENIA
refers to decrease in the number of platelets in peripheral blood (<1.5 lacs/cmm).
may result from four main mechanisms-
Increased peripheral destruction of platelets
Decreased production of platelets in bone marrow
Dilutional thrombocytopenia
Sequestration in enlarged spleen.
Platelet counts between 50,000 and 20,000/cmm usually cause mild spontaneous bleeding.
Platelet count below 20,000/cmm is associated with risk of severe haemorrhage.
8.
9.
10.
11. IDIOPATHIC THROMBOCYTOPENIC PURPURA
(ITP)
In ITP, autoantibodies or immune complexes bind to platelets and cause their premature
peripheral destruction.
Megakaryocytes are normal or increased in bone marrow.
ITP occurs in two forms—acute and chronic.
Acute ITP is a short-lasting illness which occurs in children following viral infection or
vaccination.
Chronic ITP is an disorder of insidious onset with multiple remissions and relapses,
occurs predominantly in adult women, and is not preceded by infection or associated
with any underlying disease.
12.
13. PATHOGENESIS
Acute ITP:
In acute ITP, immune complexes of viral antigens and host anti-viral antibodies
bind to Fc receptors on platelets that leads to immune destruction of platelets by
macrophages in spleen.
Alternatively, antiviral antibodies may cross-react with platelet antigens.
14. •Chronic ITP: In chronic ITP, autoantibodies are predominantly IgG.
•These antibodies are directed against specific platelet glycoproteins GpIIb/IIIa or
GpIb/IX in majority of patients. Thus, in addition to causing destruction of platelets,
these autoantibodies also induce platelet dysfunction by blocking GpIIb/IIIa
receptors.
•Antibody-coated platelets are recognised by Fc receptors on macrophages and
destroyed mainly in spleen.
15.
16. CLINICAL FEATURES- ACUTE ITP
•Incidence of ITP increases with age.
•Clinical presentation varies from severe thrombocytopenia and bleeding to
asymptomatic mild thrombocytopenia detected incidentally.
•Acute ITP predominantly affects children between 2-6 yrs of age with sex ratio 1:1.
•The disease often follows viral respiratory infection or vaccination after an interval of 2
to 3 weeks.
•There is increased incidence during winter and spring.
17. •The disease starts suddenly with mucocutaneous membrane bleeding in the
form of purpuric spots and ecchymoses (especially on legs), bleeding from
gums, nose, gastrointestinal tract and hematuria.
•Intracranial hemorrhage though rare can be fatal.
•Spleen tip may be palpable but significant splenomegaly is unusual.
•The disease is self-limited and spontaneous complete remissions usually
occur within 2 to 6 weeks in more than 80% of patients.
18. CLINICAL FEATURES- CHRONIC
ITP
Chronic ITP occurs in young adults- more common in females (3F:1M).
There is an insidious onset of superficial bleeding from skin and mucous membrane;
menorrhagia in females.
Chronic bleeding can cause iron deficiency anaemia.
History of preceding viral infection or any underlying disease is lacking.
Spleen is not palpable in chronic ITP and in the presence of splenomegaly alternative
diagnosis should be considered.
Some patients have asymptomatic thrombocytopenia and are discovered incidentally
during routine blood counts.
19. New Terminology Proposed By
International Working Group (2009)
• The term immune thrombocytopenia should be used in place of immune
thrombocytopenic purpura as bleeding is absent in majority of patients
• Primary ITP is defined as an autoimmune disorder with isolated thrombocytopenia
(platelet count <100,000/cmm) without any underlying cause.
• Secondary ITP refers to all other forms of immune thrombocytopenia except
primary ITP, e.g. drug-induced; associated with Helicobacter pylori, Hep. C virus, or HIV
• Phases of ITP:
1. Newly diagnosed: First 3 months after diagnosis
2. Persistent ITP: 3 to 12 months from diagnosis
3. Chronic ITP: >12 months
20. EXAMINATION OF PERIPHERAL
BLOOD:
•Blood loss may lead to anemia.
•In children, lymphocytes and eosinophils are frequently increased.
•In acute ITP, platelets are markedly reduced (<20,000/cmm) while in chronic ITP
platelet count is variable (usually moderately low, i.e. around 50,000/cmm).
•Morphologically, platelets are frequently large(megathrombocytes).
•In chronic ITP, bleeding manifestations are frequently mild as compared to the degree of
thrombocytopenia; this is due to the presence of large, giant platelets in circulation,
which are functionally hyperactive.
•The number of large platelets is proportional to megakaryocyte number in marrow.
21.
22. BONE MARROW EXAMINATION:
•In bone marrow, megakaryocytes are normal or increased in number and
frequently show morphological changes such as hypogranularity of
cytoplasm, vacuolisation, lack of platelet budding, nuclear non-lobulation or
hypolobulation and dense nuclear chromatin.
•These morphologic abnormalities are seen in any condition associated with
accelerated platelet destruction and are not specific for ITP.
•If clinical features, CBC, and blood smear are indicative of ITP, bone marrow
examination is not necessary for diagnosis of ITP.
23. Coagulation profile: Prolonged BT and deficient clot retraction are the
usual abnormalities.
Tests for blood coagulation are normal.
Platelet antibodies: Levels of platelet-associated immunoglobulins are raised in
majority (more than 90%) of patients with ITP.
This test, however, is neither sufficiently sensitive nor specific for ITP.
Therefore, it is not necessary for diagnosis.
24.
25. DIFFERENTIAL DIAGNOSIS
Diagnosis of ITP is one of exclusion since there are no specific clinical or lab features.
In neonates and small children- maternal ITP, FNAIT, and inherited thrombocytopenia
Drug-induced thrombocytopaenia, post transfusion isoimmune purpura by history.
Isolated thrombocytopenia in SLE.
Evans’ syndrome (immune hemolytic anemia+thrombocytopenia)
Autoimmune thrombocytopenia- lymphoma, chronic lymphocytic leukaemia
HIV is emerging as a common cause of thrombocytopenia
Hereditary thrombocytopenia (Bernard-Soulier syndrome, Wiskott-Aldrich syndrome).
26. DIAGNOSIS
Diagnosis of ITP is based on combination of following features:
• Mucocutaneous type of bleeding with abrupt onset (acute ITP) or insidious onset
(chronic ITP)
• No other abnormality on physical examination with patient otherwise being normal.
• Presence of isolated thrombocytopenia with no other abnormality on CBC.
• Bone marrow examination is usually normal.
• Exclusion of other causes of thrombocytopenia.
27.
28. TREATMENT OF ITP
• Steroids: Prednisolone, Dexamethasone, Methyleprednisolone.
• Intravenous immunoglobulin (IVIG): The mechanism of action is probably
blockade of the reticuloendothelial system, preventing phagocytosis of platelets-
The dose is 0.5 to 1 g/kg daily for 2 or 3 days, repeated every 10 to 21 days as needed.
The platelet count usually begins to rise within 2 to 4 days
29. • Other immunosuppressive drugs: mycophenolate,azathioprine (imuran)
• Rituximab (Mabthera)
• Thrombopoiesis-stimulating agents
• Recombinant FVIIa
Second-line Management
• Splenectomy: traditional second-line treatment for many years. It remains the
most effective treatment with the highest rate of complete and durable remissions.
• Thrombopoiesis-stimulating agents: support the Platelet count as long as they
are continued, but do not induce remissions. Romiplostin, Eltrombopag.
30. NEONATAL ALLOIMMUNE
THROMBOCYTOPAENIA
When the foetal platelets possessing paternally derived antigens lacking in the mother
enter maternal circulation during gestation or delivery, formation of alloantibodies is
stimulated.
These maternal antibodies cross the placenta and cause destruction of foetal platelets.
Firstborn babies are also frequently affected.
The most common platelet antigen against which antibodies form is HPA-1a (PlAl).
The condition is self-limited and usually resolves by 3 weeks (maximum 3 months)
after delivery.
31. There is a risk of intracranial haemorrhage due to trauma during vaginal delivery.
In severe cases purpura and hemorrhages are evident at birth or manifest within a few hours.
Alloimmune neonatal thrombocytopaenia should be distinguished from other causes of
thrombocytopenia as described earlier.
32. POST-TRANSFUSION PURPURA
In this very rare but life-threatening disorder, sudden onset of thrombocytopenia and
bleeding occurs about 1 week to 10 days following blood transfusion in some adult
multiparous women.
In all cases, donor platelets possess HPA-1a antigen while this antigen is lacking on
patient’s platelets.
Patients are probably sensitized previously during pregnancy by foetal platelets having
HPA-1a antigen.
The condition is treated by intravenous gamma globulin and plasmapheresis.
33. THROMBOTIC
MICROANGIOPATHIES
Thrombotic microangiopathies are characterised by microvascular
thrombosis, microangiopathic haemolytic anaemia (MAHA), and
thrombocytopaenia.
Include-
1. Thrombotic thrombocytopenic purpura (TTP)
2. Haemolytic uraemic syndrome (HUS).
34. THROMBOTIC THROMBOCYTOPENIC
PURPURA
This uncommon disorder is characterized by formation of hyaline microthrombi
in microcirculation of various organs due to aggregation of platelets.
In idiopathic TTP, autoantibodies against A disintegrin and metalloprotease
with thrombospondin type 1 motif 13 lead to deficiency of ADAMTS13 and
accumulation of ultra-large vWF multimers that bind large number of platelets.
In familial TTP (Upshaw-Sohulman syndrome) ADAMTS13 deficiency results
from mutations in ADAMTS13 gene
35. The disorder mainly affects young adults and is slightly more common in females.
The pentad of manifestations includes:
(i) Microangiopathic haemolytic anaemia: Haemolysis of red cells results from
their passage across fibrin strands of microthrombi in circulation. Clinically
patients have pallor and frequently icterus.
PBF shows presence of fragmented and nucleated red cells and reticulocytosis
(ii) Bleeding manifestations secondary to severe thrombocytopaenia such as
petechiae, ecchymoses, epistaxis and gastrointestinal/genitourinary bleeding.
36. Coagulation studies (PT, APTT) are normal in most patients;
(iii) Fluctuating neurologic dysfunction such as altered level of consciousness,
seizures, coma
(iv) Renal abnormalities: proteinuria, haematuria, azotaemia;
(v) Fever.
Most patients respond to transfusions of fresh frozen plasma or to plasmapheresis.
37.
38. HAEMOLYTIC UREMIC
SYNDROME
characterised by triad of acute renal failure, thrombocytopenia, and microangiopathic
haemolytic anaemia.
Classified into two types: typical and atypical.
Typical HUS occurs predominantly in children <5 years of age and is associated with
Shiga toxin-producing Escherichia coli O157:H7; it is characterised by a prodrome of
diarrhoeal illness followed by MAHA, thrombocytopaenia, and renal failure.
Atypical HUS has similar clinical features but is not preceded by diarrhoeal prodrome.
39.
40. Thrombocytopenia Due To Increased
Platelet Sequestration Or Pooling
Normally about 30% of total platelets in the body are sequestered in the spleen.
In conditions associated with enlargement of spleen, splenic platelet pool expands
and may reach up to 90% in some cases.
Due to compensatory increase in platelet production in bone marrow,
thrombocytopenia is usually mild.
41. PSEUDOTHROMBOCYTOPE
NIA
When platelet counts are determined by electronic cell counters on blood
samples collected in EDTA, sometimes a falsely low result may be obtained.
Examination of a parallel peripheral blood smear made from EDTA
anticoagulated blood, however, reveals large clumps of platelets and platelets
rosetting around neutrophils.
The platelet clumping results from presence of EDTA-dependent antiplatelet
antibody in some patients.
42. EDTA alters the conformation of GpIIb/IIIa complex and exposes neoantigen.
The antibody reacts with this cryptic antigen and causes platelet clumping only in vitro.
These antibodies do not have any clinical significance.
Incorrect diagnosis of thrombocytopenia can be avoided by simultaneous examination of
peripheral blood film along with determination of direct platelet count.
43.
44.
45. THROMBOCYTOSIS
•This refers to increase in the platelet count above normal (> 4 lac/cmm).
•Primary Thrombocytosis- Thrombocytosis due to myeloproliferative disorders
•It can be usually distinguished from reactive (secondary) thrombocytosis by
the presence in the former of leucocytosis and immature white cells and
nucleated red cells in peripheral blood, defective platelet function (deficient
epinephrine-induced platelet aggregation) and splenomegaly.
46. Thrombocytosis in essential thrombocythemia is associated with
thromboembolic and bleeding manifestations.
In reactive thrombocytosis, platelet count is modestly elevated and has no
clinical significance.
However, persistent thrombocytosis following splenectomy for chronic
haemolytic anaemia may result in increased risk of thromboembolic
complications if haemolysis is not completely corrected.
51. INHERITED DISORDERS OF PLATELET
FUNCTION-
BERNARD-SOULIER SYNDROME
•rare autosomal recessive congenital bleeding disorder.
•In this disease, adhesion of platelets to subendothelium is defective due to
congenital absence of glycoprotein Ib receptor complex (which consists of
GpIb, V and IX) on platelet surface.
•This receptor is essential for binding of platelets to subendothelium via vWF
•It is caused by defects in GP9,GP1BB and GP1BA genes.
52. •The haemorrhagic manifestations usually begin in infancy or early childhood.
•They are of moderate to marked degree and consist of purpuric spots, easy or
spontaneous bruising, and mucosal bleeding.
Characteristic laboratory abnormalities include-
giant platelets on peripheral blood smear
mild to moderate thrombocytopenia not proportional to the severity of bleeding,
abnormal platelet function studies (in the form of prolonged bleeding time, impaired
platelet aggregation with ristocetin not corrected by addition of normal plasma,
normal platelet aggregation with other agonists), and absence of GpIb, V, and IX.
53. No satisfactory form of therapy is available.
Severe haemorrhagic episodes are managed by platelet transfusions.
Repeated platelet transfusions can induce alloimmunisation and formation of
antibodies against glycoproteins that are absent.
54.
55. GLANZMANN’S
THROMBASTHENIA
•In this very rare autosomal recessive bleeding disorder, platelet aggregation is
deficient due to absence of GpIIb/IIIa recepter complex on platelets.
•The disorder results from mutations in genes ITGB3 (located on 17q21.32) or
ITGA2B (located on 17q21.32).
•Normally upon activation of platelets, GpIIb/IIIa receptors become exposed
on platelet surface and serve as binding sites for fibrinogen. Fibrinogen
molecules form bridges between adjacent platelets during aggregation.
56. In Glanzmann’s thrombasthenia, the absence of fibrinogen binding due to lack of
receptors is responsible for deficient aggregation.
On PBF, platelets appear small and discrete (i.e. they are not in clumps due to lack of
aggregation)
platelet count is normal
platelet function studies are abnormal (in the form of prolonged bleeding time, poor
clot retraction, platelet aggregation is absent with ADP, epinephrine, collagen, and
arachidonic acid and normal with ristocetin), and lack of GpIIb/IIIa complex.
No effective form of therapy is available. Severe haemorrhages are treated by platelet
transfusions.
57. STORAGE POOL
DEFICIENCY
Deficiency of intracellular granules of platelets is referred to as storage pool
deficiency.
It may involve dense granules, alpha granules, or both.
Dense granule storage pool deficiency: This is the most common type of
hereditary platelet function disorder. Patients usually present with mild
mucocutaneous bleeding. Electron microscopy reveals absence of dense
granules. Intraplatelet levels of ADP, serotonin, and calcium are diminished.
Ristocetin-induced aggregation is normal.
58. Alpha granule storage pool deficiency (Gray platelet syndrome): In this condition,
which has been described in only a few patients, alpha granules and their contents
are diminished or absent.
These patients have a mild bleeding diathesis.
Platelets are mildly decreased in number, are large in size, and appear pale-grey on
stained blood smears.
Defective platelet aggregation has also been described.
Reticulin fibres are increased in bone marrow.
59. ACQUIRED DISORDERS OF PLATELET
FUNCTION
Drugs- Aspirin- results in inability of the platelets to synthesise thromboxane A2 and
failure of platelet secretion. This forms the basis of use of aspirin as anti-platelet
drug in practice.
Other drugs- NSAIDS, penicillin, cephalosporins, local anaesthetics, dipyridamole,
dextran, and heparin.
Myeloproliferative neoplasms
Paraproteinaemias- coat the platelet surface and inhibit adhesion and aggregation
Uraemia- prolongation of bleeding time and impaired platelet aggregation